Atorvastatin has no effects on kidney tissues of wistar albino rats in the long-term intake: An electron microscopic study;Atorvastatina no tiene efectos sobre los tejidos renales de ratas wistar albinas en el consumo a largo plazo: Un estudio de microscopia electrónica

International Journal of Morphology

Volumn 29, Issue 1, 2011, Pages 144-150

  Aktas, Ayfer ^a   Serhan Tasdemir, M ^a   Cudi Tuncer, M ^a   Nergiz, Yusuf ^a   Akkus, Murat ^a   Bagriyanik, Hüsnü Alper ^b  

^a DICLE UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Kidney; Statins; Ultrastructural; Wistar albino rat

Indexed keywords

EID: 79957476249     PISSN: 07179367     EISSN: 07179502     Source Type: Journal    
DOI: 10.4067/S0717-95022011000100025     Document Type: Article

References (43)

1. Agarwal, R. Effects of Statins on Renal Function. Mayo Clin. Proc., 82:1381-90, 2007.
2. Agarwal, R. & Curley, T.M. The role of statins in chronic kidney disease. Am. J. Med. Sci., 330:69-81, 2005.
3. Blanco-Colio, L. M.; Tunon, J.; Martin-Ventura, J. L. & Egido, J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int., 63:12-23, 2003.
4. Buemi, M.; Allegra, A.; Corica, F.; Ruello, A.; Aloisi, C.; Pettinato, G.; Giacobbe, M.; Romeo, A. & Frisina, N. Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Clin. Pharmacol. Ther., 65:649-52, 1999.
5. Buemi, M.; Allegra, A.; Corica, F.; Aloisi, C.; Giacobbe, M.S.; Pettinato, G.; Corsonello, A.; Senatore, M. & Frisina, N. Effect of fluvastatin on proteinuria in patients with IgA nephropathy. Clin. Pharmacol. Ther., 67:427-31, 2000.
6. Casey, R. G.; Joyce, M.; Roche-Nagle, G.; Chen, G. & Bouchier-Hayes, D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J. Surg. Res., 123:176-81, 2005.
7. Chen, G. P.; Yao, L.; Lu, X., LI, L. & Hu, S. J. Tissue-specific effects of atorvastatin on 3-hydroxy-3 methylglutaryl coenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta. Pharmacol. Sin., 29:1181-6, 2008.
8. Collins, P.; Ford, I.; Croal, B.; Ball, D.; Greaves, M.; Macaulay, E. & Brittenden, J. Haemostasis, inflammation and renal function following exercise in patients with intermittent claudication on statin and aspirin therapy. Thromb. J., 4:9, 2006.
9. Diamond, J. R. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int. Suppl., 31:S29-34, 1991.
10. Dunzendorfer, S.; Rothbucher, D.; Schratzberger, P.; Reinisch, N.; Kahler, C. M. & Wiedermann, C. J. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ. Res., 81:963-9, 1997.
11. Epstein, M. & Campese, V. M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am. J. Kidney Dis., 45:2-14, 2005.
12. Fassett, R. G.; Ball, M. J.; Robertson, I. K.; Geraghty, D. P. & Coombes, J. S. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol., 18:4, 2008.
13. Gianella, A.; Nobili, E.; Abbate, M.; Zoja, C.; Gelosa, P.; Mussoni, L.; et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in strokeprone rats. Am. J. Pathol., 170(4):1165-77, 2007.
14. Goicoechea, M.; de Vinuesa, S. G.; Lahera, V.; Cachofeiro, V, Gomez-Campdera, F.; Vega, A.; et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J. Am. Soc. Nephrol., 17:S231-5, 2006.
15. Gueler, F.; Rong, S.; Park, J. K.; Fiebeler, A.; Menne, J.; Elger, M.; et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J. Am. Soc. Nephrol., 13:2288-98, 2002.
16. Guijarro, C.; Kasiske, B. L.; Kim, Y.; O'Donnel, M. P.; Lee, H. S. & Keane, W. F. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am. J. Kidney Dis., 26:152-61, 1995.
17. Harris, K. P.; Purkerson, M. L.; Yates, J. & Klahr, S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephritic syndrome. Am. J. Kidney Dis., 15:16-23, 1990.
18. Kamanna, V. S.; Pai, R.; Roh, D. D. & Kirschenbaum, M. A. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab. Invest., 74:1067-79, 1996.
19. Kandoussi, A.; Martin, F.; Hazzan, M.; Noel, C.; Fruchart, J. C.; Staels, B.; et al. HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin. Sci. (London), 103:81S-3, 2002.
20. Kasiske, B. L.; O'Donnell, M. P.; Garvis, W. J. & Keane, W. F. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ. Res., 62:367-74, 1988.
21. Kasiske, B. L; O'Donnell, M. P.; Schmitz, P. G.; Kim, Y. & Keane, W. F. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int., 37:880-91, 1990.
22. Mizuguchi, Y.; Miyajima, A.; Kosaka, T.; Asano, T.; Asano, T.; & Hayakawa, M. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J. Urol., 172:2456-9, 2004.
23. Oda, H. & Keane, W. F. Recent advances in statins and the kidney. Kidney Int., 56:S2-5, 1999.
24. O'Donnell, M. P.; Kasiske, B. L.; Kim, Y.; Schmitz, P. G. & Keane, W. F. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am. J. Kidney Dis., 22:83-9, 1993.
25. O'Donnell, M. P., Kasiske, B. L.; Katz, S. A.; Schmitz, P. G. & Keane, W. F. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension, 20:651-8, 1992.
26. Pai, R.; Kirschenbaum, M. A. & Kamana, V. S. Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int., 48:1254-62, 1995.
27. Patel, T. R. & Corbett, S. A. Mevastatin suppresses lipopolysaccharide-induced Rac activation in the human monocyte cell line THP-1. Surgery, 134:306-11, 2003.
28. Patel, T. R. & Corbett, S. A. Simvastatin suppresses LPSinduced Akt phosphorylation in the human monocyte cell line THP-1. J. Surg. Res., 116:116-20, 2004.
29. Romagnani, P.; Lasagni, L.; Mazzinghi, B.; Lazeri, E. & Romagnani, S. Pharmacological modulation of stem cell function. Curr. Med. Chem., 14:1129-39, 2007.
30. Rovin, B. H. & Tan, L. C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int., 43:218-25, 1993.
31. Sabbatini, M.; Pisani, A.; Uccello, F.; Serio, V.; Seru, R.; Paterno, R.; et al. Atorvastatin improves the course of ischemic acute renal failure in aging rats. J. Am. Soc. Nephrol., 15:901-9, 2004.
32. Sacks, F. M.; Pfeffer, M. A.; Moye, L. A.; Rouleau, J. L.; Rutherford, J. D.; Cole, T. G.; et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 335:1001-9, 1996.
33. Seliger, S. L.; Weiss, N. S.; Gillen, D. L.; Kestenbaum, B.; Ball, A.; Sherrard, D. J.; et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int., 61:297-304, 2002.
34. Sica, D. A. & Gehr, T. W. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: con- siderations in the renal failure patient. Curr. Opin. Nephrol. Hypertens., 11:123-33, 2002.
35. Shepherd, J.; Kastelein, J. J.; Bittner, V.; Deedwania, P.; Breazna, A.; Dobson, S.; et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin. J. Am. Soc. Nephrol., 2:1131-9, 2007.
36. Tashiro, K.; Makita, Y.; Shike, T.; Shirato, I.; Sato, T.; Cynshi, O.; et al. Detection of cell death of cultured mouse mesangial cells induced by oxidized low-density lipoprotein. Nephron, 82:51-8, 1999.
37. Vrtovsnik, F.; Couette, S.; Prie, D.; Lallemand, D. & Friedlander, G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int., 52:1016-27, 1997.
38. Walter, D. H.; Dimmeler, S. & Zeiher, A. M. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin. Vasc. Med., 4:385-93, 2004.
39. Welten, G. M.; Chonchol, M.; Schouten, O.; Hoeks, S.; Bax, J. J.; van Domburg, R. T.; et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol. Dial. Transplant., 23:3867-73, 2008
40. Wiesbauer, F.; Heinze, G.; Mitterbauer, C.; Harnoncourt, F.; Horl, W. H. & Oberbauer, R. Statin use is associated with prolonged survival of renal transplant recipients. J. Am. Soc. Nephrol., 19:2211-8, 2008.
41. Wong, B.; Lumma, W. C.; Smith, A. M.; Sisko, J. T.; Wright, S. D. & Cai, T. Q. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol., 69:959-62, 2001.
42. Yoshimura, A.; Inui, K.; Nemoto, T.; Uda, S.; Sugenoya, Y.; Watanabe, S.; et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J. Am. Soc. Nephrol., 9:2027-39, 1998.
43. Zhang, W.; Liu, M.; Wu, Y.; Zhu, P.; Yin, C.; Zhang, W.; et al. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J. Surg. Res., 143:428-36, 2007.